---
title: Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy
nct_id: NCT05358080
overall_status: UNKNOWN
phase: PHASE4
sponsor: Hanlim Pharm. Co., Ltd.
study_type: INTERVENTIONAL
primary_condition: Non Proliferative Diabetic Retinopathy
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05358080.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05358080"
ct_last_update_post_date: 2022-07-21
last_seen_at: "2026-05-12T06:12:55.214Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy

**Official Title:** A Multi-center, Randomized, Double-blind, Placebo-controlled, Superiority, Phase IV Trial to Evaluate the Efficacy and Safety of Entelon 50mg Compared to Placebo in Patients With Non-Proliferative Diabetic Retinopathy

**NCT ID:** [NCT05358080](https://clinicaltrials.gov/study/NCT05358080)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 396
- **Lead Sponsor:** Hanlim Pharm. Co., Ltd.
- **Conditions:** Non Proliferative Diabetic Retinopathy
- **Start Date:** 2022-05-27
- **Completion Date:** 2024-12-16
- **CT.gov Last Update:** 2022-07-21

## Brief Summary

This clinical trial is a multi-center, double-blind, randomized, placebo controlled , parallel design, superiority, phase 4 study to evaluate the efficacy and safety of Entelon 50mg in 396 patients with non-proliferative diabetic retinopathy.

## Detailed Description

This study is to prove that Entelon tab. 50mg is superior in clinical efficacy and safety compared to placebo for 24 months in patients suffering from non-proliferative diabetic retinopathy.

## Eligibility

- **Minimum age:** 19 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. 19 years ≤ age
2. Those who are diagnosed as Type 2 diabetes mellitus
3. Those whose blood sugar level has been well adjusted to less than 9% of HbA1c with dietary and oral blood sugar lowering durgs for 3 months based on the time of screening
4. Those who agree to use an effective method of contraception
5. Those who provide written consent voluntarily to participate in this clinical trial

Inclusion criteria for the study eye

1. Those with 0.5(20/40 Snellen lines) or more visual acuity
2. Those with 300 micrometers or less central macular thickness
3. Those who are diagnosed as mild to moderate NPDR(DRSS levels 35-47)

Exclusion Criteria:

1. Those who are diagnosed as proliferative diabetic retinopathy
2. Those with macular edema
3. Diabetic subjects who have difficulty in controlling blood sugar
4. Those whose blood pressure is not well controlled at the time of the screening(\>140/90mmHg)
5. Those who, have had stroke or myocardial infarction or arrhythmia that should be treated within 6 months prior to the time of screening
6. Subjects with severe renal disorder or severe liver disorder
7. Those who have a history of malignant tumors within 5 years prior to the time of screening
8. Those who are required to receive Kallidinogenase, Vaccinium myrtillus extract, Sulodexide, or Calcium dobesilate during the clinical trial period
9. Those who have an allergy to investigational product or any of its excipients
10. Those who have an allergy to fluorescein
11. Those who have galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption
12. Those who have difficulty to get OCT test or Fundus photo test
13. Pregnant or lactating woman
14. Those with medication of other investigational product within 3 months prior to the time of randomization
15. Patients who are considered to be ineligible for study participation by the investigator

Exclusion criteria for the study eye

1. Those who have a visual defect that can affect the evaluation determined by an investigator
2. Those who have a opacity that can affect the evaluation determined by an investigator
3. Those who have eye diseases that can affect the evaluation determined by an investigator
4. Those with 25mmHg or more intraocular pressure on a study eye
5. Those who are on medication of intravitreal injection of steroid or anti VEGF treatment or get laser photocoagulation within 6 months prior to the first administration
6. Those who have a history of a vitrectomy
7. Those who have a major ophthalmic surgery history within 3 months prior to the time of first administration for investigational products
8. Those who have a history of yttrium aluminum garnet capsulotomy within 2 months prior to the time of first administration for investigational products
9. Those with a phakia
```

## Arms

- **Entelon Tab. 50mg** (EXPERIMENTAL)
- **Placebo** (PLACEBO_COMPARATOR)

## Interventions

- **Entelon Tab. 50mg** (DRUG) — twice daily for 24months
- **Placebo** (DRUG) — twice daily for 24months

## Primary Outcomes

- **Proportion of subjects maintained or improved in DRSS level** _(time frame: 24 months(Visit 10))_ — Change at 24 months of treatment with the drug from baseline(day 0) in DRSS(Diabetic Retinopathy Severity Scale) level

## Secondary Outcomes

- **Proportion of subjects maintained or improved in DRSS level** _(time frame: 12 months(Visit 6))_
- **Proportion of subjects maintained or improved or worsened in DRSS** _(time frame: 12 months(Visit 6), 24 months(Visit 10))_
- **Amount of change BCVA letter** _(time frame: 24 months(Visit 10))_
- **Proportion of subjects improved or worsened in BCVA** _(time frame: 24 months(Visit 10))_
- **Change in quantitative of hard exudate** _(time frame: 6 months(Visit 4), 12 months(Visit 6), 18 months(Visit 8), 24 months(Visit 10))_
- **Change in CMT and TMV** _(time frame: 6 month(Visit 4), 12 month(Visit 6), 18 month(Visit 8), 24 month(Visit 10))_
- **Proportion of subjects with CSME** _(time frame: through study completion, an average of 2 years)_

## Locations (1)

- Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.hallym university kangnam sacred heart hospital|seoul||south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05358080.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05358080*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*